Jeffrey A. Barnes

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy

Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

Toxicities and outcome after <scp>CD19</scp>‐directed chimeric antigen receptor T‐cell therapy for secondary neurolymphomatosis

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018

Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients